Use of test
Gene fusions involving the ROS1 gene and other gene partners occur in a subset of non-small cell lung cancers (NSCLC). Such fusions carry implications regarding selection of and response to therapies. This test is included in the lung cancer focused panel, if ROS1 overexpression is detected by immunohistochemistry.
The presence of a ROS1 rearrangement in NSCLC detected by fluorescent in situ hybridisation (FISH) analysis is associated with increased sensitivity to tyrosine kinase inhibitor therapy.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis using probes located within 6q22.1.
Requesting the test
This test is usually requested by an oncologist or the pathologist providing the initial histopathology report. Please use the specific request form.
Download the solid tumour somatic mutation request form.
Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.
Please label each slide with patient and block identifiers plus number them sequentially 1-15. Stain slides 1 and 15 with H&E and leave slides 2 to 14 unstained.
The request should be accompanied by the somatic mutation request form (above) and a copy of the original histopathology report.
5 business days.
This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.
The Medicare details, including descriptor and schedule fee, are listed under MBS item 73344.
Click here for our billing policy.